The psycho-oncology digital health market is expanding as healthcare providers increasingly integrate digital mental health solutions into cancer care. Growing demand for AI-driven platforms, digital cognitive behavioral therapy, telehealth, and mobile applications is improving access to psychological support. North America leads the market, while Asia Pacific is expected to witness the fastest growth.

According to a research study published by Knowledge Sourcing Intelligence (KSI), the psycho-oncology digital health market will expand from USD 192.89 million in 2026 to USD 290.01 million in 2031 at a CAGR of 8.5% during the forecast period.
The demand for digital care solutions that provide psychological and emotional support is anticipated to see substantial growth in the market, owing to growing recognition among healthcare providers of the need to address the feelings of cancer patients.
Access sample report or view details: https://www.knowledge-sourcing.com/report/psycho-oncology-digital-health-market
Key Market Insight & Emerging Trends:
The Importance of the psycho-oncology digital health market is increasing as mental health is a key component of comprehensive cancer care today, and this is gaining traction alongside the market demand. The increasing incidence of depression, anxiety, stress, and cognitive dysfunction in cancer patients has increased the demand for easier access to personalized digital mental health solutions globally.
Digital cognitive behavioral therapy (CBT), mindfulness applications, and AI-based mental health platforms are becoming more widely used to offer ongoing emotional support, symptom management, and behavioral interventions across the continuum of cancer care. Compared with traditional face-to-face psychological services, these solutions are easier to access, and they offer better patient engagement, penetration, and scalability.
Telehealth infrastructure and the common acknowledgment of digital therapeutics have eventually fueled the market growth. Additionally, breakthroughs in artificial intelligence are creating opportunities for increasingly tailored interventions, and mobile health technologies are expanding access to care among patients located in hard-to-reach or underserved areas.
Among these regions, North America commanded the largest market share in 2025 due to significant adoption of digital therapeutics and favorable healthcare infrastructure.
Based on therapy, digital cognitive behavioral therapy (CBT) had a noteworthy share owing to its potential in managing psychological distress among cancer patients.
By indication, depression and anxiety were the dominant classes, consistent with their high burden in oncologic patients.
Based on the delivery model, mobile-based platforms accounted for the larger market share because of the growing penetration of smartphones and the rise in demand for on-the-go or remote mental health support.
Based on end user, hospitals & oncology clinics held the largest share, as these facilities integrate digital mental illness solutions into cancer care pathways.
The competitive landscape of psycho-oncology digital health is characterized by a rapidly increasing number of digital therapeutics providers, mental health technology startups, and telehealth platforms that seek to increase access to psychological care for cancer patients.
Type Insights: CBT Dominating the Market
Based on type, digital cognitive behavioral therapy (CBT) accounted for a major share of the overall market, primarily due to its rational basis and ability to provide structured psychological interventions remotely. The increasing entry of app-based CBT programs developed specifically for oncology patients is further fuelling this segment's growth.
Indication Insights: Depression and Anxiety are Driving the Demand
The two leading indication segments are depression and anxiety, as a cancer diagnosis and treatment frequently have large emotional and psychological implications. Digital mental health platforms could have the potential to provide timely support, improve emotional resilience, and result in an enhanced quality of life.
Delivery Model Insights: Care Delivery is Changing with Mobile Platforms
By solution, mobile-based solutions dominated the market owing to their convenience, ease of use, and continuous access to mental health support. Mobile platforms are becoming a more popular choice for patients, with features like symptom tracking, guided therapy sessions, meditation exercises, and AI-powered chatbots.
End User Insights: hospitals & oncology clinics maintain dominance
The market was dominated in 2025 by hospitals & oncology clinics since these segments are more aware of the need to integrate mental health support into cancer care programs. To address these challenges, many such facilities are now embracing digital psycho-oncology tools to enhance patient accessibility to psychological care and monitor patients' psychological well-being at different stages, who have the opportunity for a real-time sentinel along their treatment process.
Regional Highlights: North America Dominates while Asia Pacific Grows in Traction
North America remained the leading region in 2025, driven mainly by increasing recognition for psycho-oncology and supportive care, as well as favorable reimbursement trends for digital health technologies and the presence of key mental health technology companies. On the other hand, the Asia Pacific is anticipated to experience substantial growth throughout the assessment timeframe owing to the increasing occurrence of cancer, growing smartphone usage, and rising investments in digital healthcare infrastructure.
Competitive Landscape
The report profiles major players operating in the psycho-oncology digital health market, such as Talkspace, Inc., Akili Interactive Labs, Inc., Big Health Ltd. com, Inc., Lyra Health, Inc., Spring Health, Teladoc Health, Inc., and Twill Health. These companies are trying to focus their momentum in the psycho-oncology digital health ecosystem, such as the advancement of new AI-enabled mental healthcare solutions, tailored digital therapies, partnerships with providers for strategic expansion, and market-driven augmentation of oncology-centric mental well-being initiatives.
Market Segmentation
The report segments the psycho-oncology digital health market as follows:
By Type
Digital Cognitive Behavioral Therapy (CBT)
Mindfulness & Meditation Platforms
Psychoeducation Tools
AI-Based Mental Health Platforms
By Indication
Depression
Anxiety
Cognitive Dysfunction
Others
By Delivery Model
Mobile-Based
Web-Based
Others
By End User
Hospitals & Oncology Clinics
Specialty Mental Health Clinics
Homecare Settings
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Others
Europe
United Kingdom
Germany
Italy
France
Spain
Others
Middle East and Africa
Saudi Arabia
South Africa
Others
Asia Pacific
China
India
Japan
South Korea
Australia
Others
Companies Profiled:
Talkspace, Inc.
Akili Interactive Labs, Inc.
Big Health Ltd.
Woebot Health
Headspace Health
Calm.com, Inc.
Lyra Health, Inc.
Spring Health
Teladoc Health, Inc.
Twill Health
Explore More Reports:
Need specialized data cuts or competitive intelligence?
Our analyst team provides bespoke market sizing, supplier audits, and country-level feasibility reports tailored to your enterprise roadmap.
Speak With an Industry Analyst βPsycho-Oncology Digital Health Market - Strategic Insights and Forecasts (2026-2031)
The psycho-oncology digital health market addresses the psychological burden associated with cancer diagnosis, treatment, and survivorship through digitally delivered interventions. The market integrates behavioral therapy platforms, AI-driven engagement tools, and remote care delivery systems to manage mental health conditions in oncology populations. Demand is being shaped by increasing cancer survivorship rates, which are expanding the duration of psychological care dependency. Clinical workflows are incorporating digital interventions as oncology pathways are recognizing mental health as a determinant of treatment adherence. This integration is creating structural reliance on scalable digital platforms due to workforce shortages in psycho-oncology specialists.Healthcare systems are shifting toward decentralized care models, which are enabling home-based psychological support delivery for oncology patients. This shift is reducing dependency on in-person mental health services, while increasing demand for asynchronous and continuous monitoring tools. The market is transitioning from general wellness applications toward clinically validated digital therapeutics tailored for oncology populations. This transformation is establishing digital psycho-oncology as a critical extension of cancer care infrastructure.
Ask an Industry Analyst
Have questions regarding this briefing or market projections? Inquire with our sector lead.
Related Press Releases
View All β
ADC Manufacturing & CDMO Market is expected to reach USD 10.49 billion by 2031
Aug 7, 2026
Lifestyle-Associated Cancer Epidemiology Market is expected to reach USD 13.12 billion by 2031
Aug 5, 2026
Intratumoral Injection Therapy Market is expected to reach USD 630.39 million by 2031
Jul 24, 2026
Palliative Care in Oncology Market is expected to reach USD 244.1 billion by 2031
Jul 22, 2026
Oncology Drug Resistance Testing Market is projected to reach USD 3.41 billion in 2031 at a CAGR of 6.6 %
Jul 20, 2026More Press Releases
TROP-2 Targeted Therapy Market is anticipated to surpass USD 3.29 billion in 2031 at a CAGR of 8.6 %
The TROP-2 Targeted Therapy market is expanding rapidly due to increasing precision oncology adoption, rising cancer prevalence, and growing use of antibody-drug conjugates. North America leads the market, while Asia Pacific shows the fastest growth. Continuous clinical trials, regulatory approvals, and strategic collaborations are accelerating innovation and commercial adoption worldwide.
Second Primary Cancer Prevention Market is expected to reach USD 24.7 billion by 2031
The Second primary cancer prevention refers to strategies aimed at reducing the risk of developing a new, unrelated cancer in individuals with a prior cancer diagnosis. Growing cancer survivorship, advances in treatment, and increasing awareness of long-term health outcomes have heightened the importance of prevention and surveillance programs. Key approaches include routine screening, genetic risk assessment, lifestyle modification, and long-term follow-up care. Government agencies and healthcare organisations increasingly emphasise survivorship care plans and evidence-based screening protocols to detect new malignancies at earlier stages. Continued investments in early detection technologies and personalised risk assessment are expected to support advancements in second primary cancer prevention.
Synthetic Lethality Drug Market is expected to reach USD 4.31 billion by 2031
The worldwide market for Synthetic Lethality Drug Market is expected to witness significant growth due to an increasing adoption of precision oncology approaches as well as the rising prevalence of genetically driven cancers. Synthetic lethality-based therapies are considered efficient as they are transforming cancer treatment by targeting tumor-specific genetic vulnerabilities, which minimizes damage to healthy cells. Multiple growing investments in genomic research, next-generation sequencing technologies, and biomarker discovery are also accelerating their identification of novel synthetic legal targets. Additionally, increasing regulatory support for targeted therapies, advancements in companion diagnostics, as well as expansion of clinical trial activity are factors that are contributing to market expansion.